- Home
- NMS vs PMVP Comparison
NMS vs PMVP Comparison
Compare NMS & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | PMVP |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2M | 66.1M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMS | PMVP |
|---|---|---|
| Price | $11.03 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.4K | ★ 324.8K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.99 | $1.02 |
| 52 Week High | $12.50 | $1.88 |
Technical Indicators
Market Signals| Indicator | NMS | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 21.38 | 58.16 |
| Support Level | N/A | $1.04 |
| Resistance Level | $12.03 | $1.33 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 5.78 | 78.57 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.